Drugs / BHV-2100
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06603623 | Oct 2024 → Mar 2025 | migraine disorder | Biohaven Therapeutics Ltd. | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BHV-2100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06603623 ↗ |